Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Got story updates? Submit your updates here. ›

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, announced that it will participate in one-on-one investor meetings at the upcoming Raymond James Biotech Innovation Symposium in New York City on April 14th, 2026.

Why it matters

Tvardi's participation in the prestigious Raymond James Biotech Innovation Symposium represents an important opportunity for the company to showcase its pipeline of STAT3-targeting therapies to a wide audience of potential investors and industry partners. STAT3 is a key signaling pathway involved in various inflammatory and proliferative diseases, making Tvardi's novel therapies a potential solution for unmet medical needs.

The details

Tvardi is currently conducting clinical trials with its lead candidates TTI-101 in hepatocellular carcinoma and TTI-109 in healthy volunteers. The company's small molecule therapies aim to target the STAT3 signaling pathway, which plays a central role in driving uncontrolled proliferation, survival, and immune dysregulation across various diseases.

• The Raymond James Biotech Innovation Symposium will take place on April 14th, 2026 in New York City.

What’s next

Tvardi's participation in the Raymond James Biotech Innovation Symposium will provide the company with an opportunity to engage in one-on-one meetings with potential investors and industry partners, potentially leading to future collaborations or funding opportunities to support the development of its STAT3-targeting therapies.